Biotech Exit: Million Arcellx Sparks Investor Reassessment
A notable stake sale in Arcellx turned heads in biotech investing. This article unpack the $26 million exit, why the ...
Glide paths in target date funds describe how asset allocations shift automatically as retirement nears, balancing growth and risk over time. This intro explains the idea and why it matters for planning.
25,488 articlesA notable stake sale in Arcellx turned heads in biotech investing. This article unpack the $26 million exit, why the ...
Three monthly dividend ETFs are drawing attention for steady payouts and yields that beat Treasuries. This piece brea...
Mega-cap leadership keeps steering the bull market. AIC rally and AI-driven spend lift MGK, SCHG, and IWF as investor...
As markets swing and tax rules shift, households with a $450K+ 401K are weighing year-end charity moves. A Donor-Advi...
VOO remains the default way to own the market, but cheaper S&P 500 ETFs challenge the long-held view. The difference ...
A specialized REIT with cannabis-related tenants moved higher in today’s session. This article breaks down the factor...
A Teton County refund of a $24,325 affordable housing fee follows a constitutional challenge, signaling potential bro...
In a year of volatile rates, Vanguard’s cheapest short-term bond ETF stands out for ultra-low fees and solid near-ter...
A single AI infrastructure stock delivered an eye-popping 4,800% gain in 12 months. Here’s what drove that rally, wha...
XRP ETFs posted their first weekly red bar after months of inflows, while Bitcoin and Ethereum ETFs logged solid gain...
As markets enter 2026, a century of stock market data underpins a new wave of strategy. This piece distills three les...
Oil’s surge fuels a wave of gains in key energy ETFs, led by XLE, OIH, and PBT, as supply, demand, and drilling budge...